<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642288</url>
  </required_header>
  <id_info>
    <org_study_id>Gastrografin-CRE</org_study_id>
    <nct_id>NCT03642288</nct_id>
  </id_info>
  <brief_title>The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction</brief_title>
  <official_title>The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction：A Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinling Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jinling Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic radiation enteropathy (CRE) is a major issue for long-term cancer survivors. The aim
      of this study was to clarify the diagnostic and therapeutic effect of the Gastrografin (GG)
      challenge for patients with CRE induced small bowel obstruction SBO.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of successful conservative treatment</measure>
    <time_frame>5 days</time_frame>
    <description>The rate of patients who need for operative intervention within 48 hours of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to resolution</measure>
    <time_frame>2 weeks</time_frame>
    <description>The time to resolution of ASIO (flatus and bowel motion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of hospital stays</measure>
    <time_frame>2 weeks</time_frame>
    <description>The length of hospital stays (in hours, calculated from the hospital admission to resolution of intestinal obstruction).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>CRE-induced SBO</condition>
  <arm_group>
    <arm_group_label>CRE-induced SBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CRE-induced SBO received GG challenge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASBO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with adhesive SBO (ASBO) received GG challenge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gastrografin</intervention_name>
    <description>Patients with CRE-induced SBO or ASBO both received GG challenge.</description>
    <arm_group_label>ASBO</arm_group_label>
    <arm_group_label>CRE-induced SBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  with a first diagnosis of CRE combined with SBO and ASBO that was determined by
             clinical history, computed tomography (CT) manifestation, and conﬁrmed by
             intraoperative and histologic ﬁndings.

          -  radiation therapy completed at least 6 months before enrolment.

        Exclusion Criteria:

          -  a colostomy or ileostomy;

          -  large bowel obstruction;

          -  with a known history of either allergy or hypersensitivity to iodinated contrast
             agents;

          -  with signs of strangulation;

          -  metastatic disease;

          -  obstruction within 4 weeks after a recent operation or serious comorbidity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinling Hospital, China</investigator_affiliation>
    <investigator_full_name>Ding Chao</investigator_full_name>
    <investigator_title>Clinical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Obstruction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

